Low-dose rate brachytherapy for patients with low or intermediate-risk prostate cancer. Analysis of relapse-free survival
Purpose. Evaluate the clinical results of treating patients with localized prostate cancer after low-dose-rate (LDR) brachytherapy. Determine the significance of prognostic factors affecting biochemical free survival.
Materials and methods. 290 patients with low and intermediate risks prostate cancer were given LDR brachytherapy as monotherapy. The patient recruitment period from 2010 to 2017 y. Biochemical relapse was determined according to Phoenix criteria (PSA nadir + 2 ng / ml).